Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in GeneDx Holdings Corp. (NASDAQ:WGS)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired 15,317 shares of GeneDx Holdings Corp. valued at approximately $1,357,000, representing about 0.05% of the company.
• Institutional investors currently own 61.72% of GeneDx, with significant acquisitions from firms like Ameriprise Financial Inc. and GAMMA Investing LLC.
• GeneDx's recent earnings report showed $0.50 earnings per share, surpassing expectations and highlighting a revenue of $102.69 million for the quarter.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 15,317 shares of the company's stock, valued at approximately $1,357,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.05% of GeneDx at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Morse Asset Management Inc purchased a new position in GeneDx in the 1st quarter worth about $1,808,000. Hussman Strategic Advisors Inc. purchased a new stake in shares of GeneDx during the 1st quarter valued at about $2,790,000. Jackson Creek Investment Advisors LLC purchased a new stake in shares of GeneDx during the 1st quarter valued at about $1,378,000. Jennison Associates LLC purchased a new stake in shares of GeneDx during the 1st quarter valued at about $563,000. Finally, Victory Capital Management Inc. increased its position in shares of GeneDx by 475.9% during the 1st quarter. Victory Capital Management Inc. now owns 15,665 shares of the company's stock valued at $1,387,000 after purchasing an additional 12,945 shares during the last quarter. Institutional investors own 61.72% of the company's stock.

GeneDx Price Performance

WGS traded down $1.20 during trading on Tuesday, reaching $107.16. 313,337 shares of the company traded hands, compared to its average volume of 1,086,896. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87. GeneDx Holdings Corp. has a 12-month low of $28.14 and a 12-month high of $117.75. The firm has a fifty day simple moving average of $80.76 and a 200 day simple moving average of $83.41. The company has a market cap of $3.06 billion, a P/E ratio of 2,144.72 and a beta of 2.02.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The firm had revenue of $102.69 million during the quarter, compared to analyst estimates of $86.00 million. On average, equities analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on WGS shares. TD Securities reduced their price target on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Guggenheim restated a "buy" rating and set a $115.00 target price (up previously from $88.00) on shares of GeneDx in a research note on Monday, June 30th. Wells Fargo & Company raised their target price on shares of GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Wall Street Zen upgraded shares of GeneDx from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Jefferies Financial Group upgraded shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 target price on the stock in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $101.63.

Insider Activity at GeneDx

In other news, Director Keith A. Meister acquired 100,000 shares of the company's stock in a transaction on Thursday, May 8th. The stock was bought at an average cost of $56.01 per share, with a total value of $5,601,000.00. Following the completion of the purchase, the director directly owned 3,008,629 shares of the company's stock, valued at $168,513,310.29. This represents a 3.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kevin Feeley sold 5,278 shares of GeneDx stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $93.00, for a total transaction of $490,854.00. Following the transaction, the chief financial officer directly owned 3,392 shares of the company's stock, valued at $315,456. The trade was a 60.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,411 shares of company stock valued at $2,085,051. 29.60% of the stock is owned by corporate insiders.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.